150 related articles for article (PubMed ID: 17577024)
1. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
Henry NL; Hayes DF
J Clin Oncol; 2007 Jun; 25(18):2501-3. PubMed ID: 17577024
[No Abstract] [Full Text] [Related]
2. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
[TBL] [Abstract][Full Text] [Related]
3. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Panasci LC
J Clin Oncol; 2006 May; 24(15):2392; author reply 2392. PubMed ID: 16710042
[No Abstract] [Full Text] [Related]
4. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
Albain KS
J Natl Cancer Inst; 2004 Dec; 96(24):1801-4. PubMed ID: 15601631
[No Abstract] [Full Text] [Related]
5. [A randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients].
Sack H
Strahlenther Onkol; 1995 Jun; 171(6):360-1. PubMed ID: 7597623
[No Abstract] [Full Text] [Related]
6. Evolving concepts in the systemic adjuvant treatment of breast cancer.
Bonadonna G
Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
[No Abstract] [Full Text] [Related]
7. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
8. Adjuvant therapy for early breast cancer.
Costa SD; Bischoff J
N Engl J Med; 2007 Mar; 356(12):1268-9. PubMed ID: 17377168
[No Abstract] [Full Text] [Related]
9. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
10. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
11. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
12. [Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
Garin AM; Dmitrieva NV; Vyshinskaia GV; Lichintser MR
Vopr Onkol; 1987; 33(11):13-7. PubMed ID: 3686916
[TBL] [Abstract][Full Text] [Related]
13. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Sauter C
Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
[No Abstract] [Full Text] [Related]
14. [Adjuvant therapy of breast cancer. 1: Cytostatic therapy].
Possinger K; Sauer HJ; Wilmanns W
Fortschr Med; 1986 Aug; 104(29):552-5. PubMed ID: 3758881
[No Abstract] [Full Text] [Related]
15. Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer.
Bonadonna G; Valagussa P; Veronesi U
J Clin Oncol; 2008 Jan; 26(3):342-4. PubMed ID: 18202404
[No Abstract] [Full Text] [Related]
16. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
17. Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer.
Coccaro M; Gallucci G
J Clin Oncol; 2008 Jul; 26(19):3288; author reply 3289. PubMed ID: 18591567
[No Abstract] [Full Text] [Related]
18. [Breast cancer adjuvants: results of a DUR (drug utilization research) study].
Nuzzo A
Suppl Tumori; 2004; 3(4):S86-7. PubMed ID: 15206223
[No Abstract] [Full Text] [Related]
19. [Complete regression of breast cancer and its lung metastases after chemohormonotherapy].
Borisov VI; Vorob'ev AN; Stsetsevich NV; Ass NIa
Sov Med; 1986; (12):123-4. PubMed ID: 3563699
[No Abstract] [Full Text] [Related]
20. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
Samur M; Bozcuk HS
J Clin Oncol; 2003 Jun; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
[No Abstract] [Full Text] [Related]
[Next] [New Search]
